Bioxcel Therapeutics Inc (BTAI) Stock Price, Quote & News

Company Profile

BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 475 238 6837

Website: www.bioxceltherapeutics.com

Address:

555 Long Wharf Drive, 12th Floor, New Haven, United States

J_machete Apr. 25 at 6:41 AM

$BTAI is more dillution needed until november??

0 · Reply

AllAboutTheBread Apr. 25 at 2:44 AM

$BTAI give or take a few days…yes

0 · Reply

wndyctyboy1975 Apr. 25 at 12:23 AM

$BTAI this is where this stock stays till November

0 · Reply

buloyloy Apr. 24 at 3:49 PM

$BTAI good entry now? Hmm

2 · Reply

Nickandrun Apr. 24 at 2:03 PM

$BTAI weak meeting yesterday but at the very least management sounded pretty optimistic about their product. CEO kinda dodged the question of “is there any body else that is gonna help you fund the products release for at home” so my guess is they are gonna try to go the independent route to see if they’ll be profitable first and if not offer the product to multiple potential partners or a buyout.

0 · Reply

AllAboutTheBread Apr. 24 at 2:02 PM

$BTAI snagged another 70 at 1.07.

0 · Reply

wndyctyboy1975 Apr. 24 at 1:34 PM

$BTAI did anyone else hear this crap has a 17.00 rating??? what a crock!!

0 · Reply

Paxhawig Apr. 24 at 12:29 PM

$BTAI welcome rs

1 · Reply

wndyctyboy1975 Apr. 23 at 11:38 PM

$BTAI so the meeting told us a bunch of stuff we already knew?? Why bother wasting theirs time??

0 · Reply

AllAboutTheBread Apr. 23 at 10:28 PM

$BTAI Sure glad that big meeting pushed us 200%, i bought 50 more shares at 1.09 cause im built different.

0 · Reply

BioXcel Therapeutics Transcript: Investor update

Apr 17, 2026, 7:00 AM EDT - 8 days ago

BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting

Apr 9, 2026, 7:53 PM EDT - 15 days ago

Did BioXcel Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Apr 8, 2026, 7:00 AM EDT - 17 days ago

BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions

Apr 1, 2026, 7:00 AM EDT - 24 days ago

BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting

Mar 27, 2026, 7:00 AM EDT - 4 weeks ago

BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient Setting

Mar 11, 2026, 4:20 PM EDT - 6 weeks ago

BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering

Mar 10, 2026, 2:36 PM EDT - 6 weeks ago

BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering

Mar 6, 2026, 10:27 AM EST - 7 weeks ago

Why Are BioXcel Therapeutics Shares Down Friday?

Mar 5, 2026, 8:53 AM EST - 7 weeks ago

BioXcel Therapeutics Stock Rallies Opioid Study Success

Mar 5, 2026, 7:00 AM EST - 7 weeks ago

BioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatment of Opioid Withdrawal

Feb 27, 2026, 2:00 PM EST - 2 months ago

BioXcel Therapeutics Transcript: Status update

Feb 19, 2026, 7:00 AM EST - 2 months ago

BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer's Dementia

Jan 20, 2026, 7:00 AM EST - 3 months ago

BioXcel Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for IGALMI® Label Expansion in the At-Home Setting

Jan 15, 2026, 12:44 PM EST - 3 months ago

Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Jan 12, 2026, 7:00 AM EST - 3 months ago

BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting

Jan 7, 2026, 7:00 AM EST - 3 months ago

BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI®

Dec 12, 2025, 9:00 AM EST - 4 months ago

BioXcel Therapeutics Transcript: AGM 2025

Dec 3, 2025, 7:00 AM EST - 5 months ago

Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions

Nov 12, 2025, 7:00 AM EST - 5 months ago

BioXcel Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on Late-Stage Clinical Programs for Agitation in Bipolar, Schizophrenia, and Alzheimer's Disease

Oct 14, 2025, 7:00 AM EDT - 6 months ago

BioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy Outcomes

Oct 13, 2025, 7:00 AM EDT - 6 months ago

BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation

Sep 18, 2025, 7:00 AM EDT - 7 months ago

BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements

Sep 10, 2025, 3:08 PM EDT - 8 months ago

BioXcel Drug Calms Agitation At Home For Schizophrenia, Bipolar Patients

Sep 10, 2025, 2:00 PM EDT - 8 months ago

BioXcel Therapeutics Transcript: Study Result

Sep 10, 2025, 6:30 AM EDT - 8 months ago

BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia

Sep 8, 2025, 4:30 PM EDT - 8 months ago

BioXcel Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 7:00 AM EDT - 8 months ago

BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 27, 2025, 12:01 PM EDT - 8 months ago

BioXcel Seeks FDA Label Expansion For Schizophrenia Treatment

Aug 27, 2025, 8:00 AM EDT - 8 months ago

UPDATE -- BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®

Aug 27, 2025, 8:00 AM EDT - 8 months ago

BioXcel Therapeutics Transcript: Study Update

Aug 27, 2025, 7:29 AM EDT - 8 months ago

BioXcel's agitation drug meets main goal in at-home study

Aug 27, 2025, 7:00 AM EDT - 8 months ago

BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®

Aug 26, 2025, 4:00 PM EDT - 8 months ago

BioXcel Therapeutics To Announce Topline Results from SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia on August 27, 2025

Aug 19, 2025, 7:00 AM EDT - 8 months ago

BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Aug 18, 2025, 7:00 AM EDT - 8 months ago

BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia

Aug 14, 2025, 1:00 PM EDT - 9 months ago

BioXcel Therapeutics Transcript: H.C. Wainwright & Co. “HCW@Home” Series 2025

Aug 13, 2025, 7:00 AM EDT - 9 months ago

BioXcel Therapeutics to Participate in the H.C. Wainwright & Co. “HCW@Home” Series

Aug 12, 2025, 12:00 PM EDT - 9 months ago

BioXcel Therapeutics Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Aug 12, 2025, 7:55 AM EDT - 9 months ago

BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates

Aug 11, 2025, 7:00 AM EDT - 9 months ago

BioXcel Therapeutics to Participate in Canaccord Genuity 45th Annual Growth Conference

Aug 6, 2025, 7:00 AM EDT - 9 months ago

BioXcel Therapeutics Announces Publication in Frontiers in Pharmacology on the Effects of Dexmedetomidine (the active ingredient in BXCL-501) on Stress-Mediated Behaviors in Non-clinical Studies

Aug 1, 2025, 7:00 AM EDT - 9 months ago

BioXcel Therapeutics Announces Last Patient Last Visit in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Jul 21, 2025, 7:00 AM EDT - 9 months ago

BioXcel Therapeutics Submits Pre-Supplemental New Drug Application Meeting Package in Support of Potential Label Expansion for IGALMI®

Jul 1, 2025, 7:00 AM EDT - 10 months ago

BioXcel Therapeutics Receives Second Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

May 27, 2025, 8:01 AM EDT - 11 months ago

BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

May 27, 2025, 7:00 AM EDT - 11 months ago

BioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirement

May 12, 2025, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Mar 27, 2025, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024

Mar 11, 2025, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Mar 7, 2025, 7:00 AM EST - 1 year ago

BioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Mar 4, 2025, 4:15 PM EST - 1 year ago

BioXcel Therapeutics Announces Closing of $14 Million Registered Direct Offering

Mar 3, 2025, 3:33 PM EST - 1 year ago

BioXcel Therapeutics Announces $14 Million Registered Direct Offering

Mar 3, 2025, 7:00 AM EST - 1 year ago

BioXcel Therapeutics Announces FDA Closed its Inspection of Site for Phase 3 TRANQUILITY II Trial for Acute Treatment of Agitation Associated with Alzheimer's Dementia

Feb 28, 2025, 7:00 AM EST - 1 year ago

BioXcel Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

Feb 6, 2025, 7:00 AM EST - 1 year ago

BioXcel Therapeutics Announces Reverse Stock Split

Nov 22, 2024, 8:16 AM EST - 1 year ago

BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering

Nov 21, 2024, 4:47 PM EST - 1 year ago

BioXcel Therapeutics Announces Proposed Public Offering

Nov 14, 2024, 8:00 AM EST - 1 year ago

BioXcel Therapeutics Earnings Call Transcript: Q3 2024

Aug 13, 2024, 1:00 PM EDT - 1 year ago

BioXcel Therapeutics Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024

Aug 6, 2024, 8:00 AM EDT - 1 year ago

BioXcel Therapeutics Earnings Call Transcript: Q2 2024

Jun 5, 2024, 3:00 PM EDT - 2 years ago

BioXcel Therapeutics Transcript: Jefferies Global Healthcare Conference

May 9, 2024, 8:00 AM EDT - 2 years ago

BioXcel Therapeutics Earnings Call Transcript: Q1 2024

Mar 12, 2024, 8:00 AM EDT - 2 years ago

BioXcel Therapeutics Earnings Call Transcript: Q4 2023

Dec 12, 2023, 1:00 PM EST - 2 years ago

BioXcel Therapeutics Transcript: R&D Day 2023

Nov 14, 2023, 8:00 AM EST - 2 years ago

BioXcel Therapeutics Earnings Call Transcript: Q3 2023

Oct 10, 2023, 8:00 AM EDT - 2 years ago

BioXcel Therapeutics Transcript: Study Result

Aug 14, 2023, 8:00 AM EDT - 2 years ago

BioXcel Therapeutics Earnings Call Transcript: Q2 2023

Jun 29, 2023, 8:00 AM EDT - 3 years ago

BioXcel Therapeutics Transcript: Study Result

Jun 14, 2023, 5:40 PM EDT - 3 years ago

BioXcel Therapeutics Transcript: Goldman Sachs 44th Annual Global Healthcare Conference

May 25, 2023, 8:00 AM EDT - 3 years ago

BioXcel Therapeutics Transcript: Study Result

May 8, 2023, 8:00 AM EDT - 3 years ago

BioXcel Therapeutics Earnings Call Transcript: Q1 2023

Mar 9, 2023, 8:30 AM EST - 3 years ago

BioXcel Therapeutics Earnings Call Transcript: Q4 2022

Jan 11, 2023, 12:45 PM EST - 3 years ago

BioXcel Therapeutics Transcript: JPMorgan Healthcare Conference

Nov 10, 2022, 10:45 AM EST - 3 years ago

BioXcel Therapeutics Earnings Call Transcript: Q3 2022

Oct 18, 2022, 11:00 AM EDT - 3 years ago

BioXcel Therapeutics Transcript: Commercial Day 2022

Aug 9, 2022, 8:30 AM EDT - 4 years ago

BioXcel Therapeutics Earnings Call Transcript: Q2 2022

May 9, 2022, 8:30 AM EDT - 4 years ago

BioXcel Therapeutics Earnings Call Transcript: Q1 2022

Apr 6, 2022, 8:30 AM EDT - 4 years ago

BioXcel Therapeutics Transcript: FDA Announcement

Mar 10, 2022, 8:30 AM EST - 4 years ago

BioXcel Therapeutics Earnings Call Transcript: Q4 2021

Nov 10, 2021, 8:30 AM EST - 4 years ago

BioXcel Therapeutics Earnings Call Transcript: Q3 2021

Sep 23, 2021, 12:00 PM EDT - 4 years ago

BioXcel Therapeutics Transcript: R&D Day

Aug 10, 2021, 8:30 AM EDT - 5 years ago

BioXcel Therapeutics Earnings Call Transcript: Q2 2021

Jun 25, 2021, 12:00 PM EDT - 5 years ago

BioXcel Therapeutics Transcript: Commercial Day

Jun 11, 2021, 9:00 AM EDT - 5 years ago

BioXcel Therapeutics Transcript: AGM 2021

May 10, 2021, 8:30 AM EDT - 5 years ago

BioXcel Therapeutics Earnings Call Transcript: Q1 2021

Mar 11, 2021, 8:30 AM EST - 5 years ago

BioXcel Therapeutics Earnings Call Transcript: Q4 2020

Jan 5, 2021, 8:30 AM EST - 5 years ago

BioXcel Therapeutics Transcript: Study Result

Nov 12, 2020, 8:30 AM EST - 5 years ago

BioXcel Therapeutics Earnings Call Transcript: Q3 2020

Aug 14, 2020, 8:30 AM EDT - 6 years ago

BioXcel Therapeutics Earnings Call Transcript: Q2 2020

Jul 20, 2020, 8:30 AM EDT - 6 years ago

BioXcel Therapeutics Transcript: Study Result

May 20, 2020, 9:00 AM EDT - 6 years ago

BioXcel Therapeutics Transcript: AGM 2020

May 12, 2020, 8:30 AM EDT - 6 years ago

BioXcel Therapeutics Earnings Call Transcript: Q1 2020

Mar 9, 2020, 8:30 AM EDT - 6 years ago

BioXcel Therapeutics Earnings Call Transcript: Q4 2019

Nov 14, 2019, 8:30 AM EST - 7 years ago

BioXcel Therapeutics Earnings Call Transcript: Q3 2019

Aug 6, 2019, 8:30 AM EDT - 7 years ago

BioXcel Therapeutics Earnings Call Transcript: Q2 2019

Jul 22, 2019, 8:30 AM EDT - 7 years ago

BioXcel Therapeutics Transcript: Study Result

May 22, 2019, 8:30 AM EDT - 7 years ago

BioXcel Therapeutics Transcript: Study Update

May 20, 2019, 8:30 AM EDT - 7 years ago

BioXcel Therapeutics Transcript: Study Result

May 7, 2019, 8:30 AM EDT - 7 years ago

BioXcel Therapeutics Earnings Call Transcript: Q1 2019

Mar 7, 2019, 8:30 AM EST - 7 years ago

BioXcel Therapeutics Earnings Call Transcript: Q4 2018

Jan 3, 2019, 11:30 AM EST - 7 years ago

BioXcel Therapeutics Transcript: Study Result

Nov 9, 2018, 8:00 AM EST - 8 years ago

BioXcel Therapeutics Earnings Call Transcript: Q3 2018

Aug 8, 2018, 4:30 PM EDT - 8 years ago

BioXcel Therapeutics Earnings Call Transcript: Q2 2018

J_machete Apr. 25 at 6:41 AM

$BTAI is more dillution needed until november??

0 · Reply

AllAboutTheBread Apr. 25 at 2:44 AM

$BTAI give or take a few days…yes

0 · Reply

wndyctyboy1975 Apr. 25 at 12:23 AM

$BTAI this is where this stock stays till November

0 · Reply

buloyloy Apr. 24 at 3:49 PM

$BTAI good entry now? Hmm

2 · Reply

Nickandrun Apr. 24 at 2:03 PM

0 · Reply

AllAboutTheBread Apr. 24 at 2:02 PM

$BTAI snagged another 70 at 1.07.

0 · Reply

wndyctyboy1975 Apr. 24 at 1:34 PM

$BTAI did anyone else hear this crap has a 17.00 rating??? what a crock!!

0 · Reply

Paxhawig Apr. 24 at 12:29 PM

$BTAI welcome rs

1 · Reply

wndyctyboy1975 Apr. 23 at 11:38 PM

$BTAI so the meeting told us a bunch of stuff we already knew?? Why bother wasting theirs time??

0 · Reply

AllAboutTheBread Apr. 23 at 10:28 PM

$BTAI Sure glad that big meeting pushed us 200%, i bought 50 more shares at 1.09 cause im built different.

0 · Reply

MakeM0ney_444 Apr. 23 at 7:47 PM

$BTAI so wtf happened what was the meeting about????

1 · Reply

Brody71 Apr. 23 at 7:11 PM

$BTAI quietly holding while everyone’s chasing dead runners… This is exactly how they set up before a move Tight base + catalyst window = pressure building All it takes is one PR and this doesn’t stay at $1 long Most people won’t notice until it’s already moving I’m watching for $1.25 break 🔥 * #Biotech * #LowFloat * #SmallCaps * #Momentum * #AfterHours * #Premarket * #StocksToWatch

0 · Reply

Paulbpaulb Apr. 23 at 7:11 PM

$BTAI at this price, buy buy buy!

0 · Reply

Brody71 Apr. 23 at 6:51 PM

$BTAI coiling at $1 while the rest of the market bleeds… This is how runners look BEFORE they go Tight base + catalyst window = explosive setup After hours / premarket is where this moves Seen this setup too many times $1.50 comes quick if it triggers Eyes here 👀🔥 #StocksToWatch #LowFloat #Biotech #Runner

0 · Reply

MakeM0ney_444 Apr. 23 at 6:26 PM

$BTAI what the hell kind of update???? Was this planned??? Partnership???? BUYOUT???

2 · Reply

gello2000 Apr. 23 at 6:09 PM

$BTAI who's ready for the reverse split announcement then offering?

1 · Reply

Duskfall Apr. 23 at 6:00 PM

$BTAI Still here 💯

1 · Reply

wndyctyboy1975 Apr. 23 at 4:08 PM

$BTAI wonder what the update brings??? Hopefully something good!!!

0 · Reply

Nickandrun Apr. 23 at 2:19 PM

$BTAI

0 · Reply

Brody71 Apr. 23 at 1:29 PM

$BTAI 👉 $BTAI * Completely different look: * Tight consolidation 1.13–1.20 * Holding range (this is bullish behavior) * Not breaking down 👉 This is what a setup BEFORE a move looks like

0 · Reply

Brody71 Apr. 23 at 1:14 PM

$BTAI Top Scanner Watch (Right Now) 1. BTAI * Status: Still active (you’re in the right one) * Why it’s on scanner: * Event/catalyst driven (this is key) * Holding near lows = bounce potential * Volume keeps reappearing on dips * Setup: * If it holds ~1.15–1.20 → bounce to 1.35–1.50 * Break of 1.50 = momentum + possible squeeze * Verdict: 👉 Still one of the best plays on the board right now #ShortSqueeze #GammaSqueeze #Breakout #Momentum #Runner #Bullish #DipBuy #Reversal #Volume $BTAI #BTAI #Biotech #SmallCap #LowFloat

0 · Reply

AllAboutTheBread Apr. 23 at 1:11 PM

$BTAI another spam pumper. this means nothing, stock price will most likely go down today with overall market.

2 · Reply

Market Cap	29.78M
Revenue (ttm)	640,000.00
Net Income (ttm)	-69.90M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-10,921.88%
Debt to Equity Ratio	-1.15

Volume	489,600
Avg Vol	1,767,830
Day's Range	N/A - N/A
Shares Out	27.08M
Stochastic %K	20%
Beta	0.30
Analysts	Strong Sell
Price Target	$14.60